MBX Biosciences Inc. Comm... (MBX)
NASDAQ: MBX
· Real-Time Price · USD
13.77
-0.18 (-1.29%)
At close: Oct 16, 2025, 3:59 PM
13.55
-1.60%
After-hours: Oct 16, 2025, 07:39 PM EDT
-1.29% (1D)
| Bid | 13.39 |
| Market Cap | 462.58M |
| Revenue (ttm) | 222K |
| Net Income (ttm) | -77.02M |
| EPS (ttm) | -6.24 |
| PE Ratio (ttm) | -2.21 |
| Forward PE | -4.66 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 13.95 |
| Volume | 588,815 |
| Avg. Volume (20D) | 1,176,582 |
| Open | 14.00 |
| Previous Close | 13.95 |
| Day's Range | 13.17 - 14.45 |
| 52-Week Range | 4.81 - 27.50 |
| Beta | 0.81 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for MBX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-13.78%
MBX Biosciences shares are trading lower after the...
Unlock content with
Pro Subscription
3 weeks ago
+100%
MBX Biosciences shares are trading higher after the company announced once-weekly Canvuparatide achieved the primary endpoint in a Phase 2 trial.
3 weeks ago · seekingalpha.com
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows MarketMBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and co...
2 months ago · fool.com
Mbx Biosciences (MBX) Q2 Loss Widens 22%Mbx Biosciences (MBX) Q2 Loss Widens 22%